Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · IEX Real-Time Price · USD
6.89
+0.07 (1.03%)
At close: Jul 19, 2024, 4:00 PM
6.99
+0.10 (1.45%)
Pre-market: Jul 22, 2024, 7:44 AM EDT
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Verve Therapeutics stock have an average target of 33, with a low estimate of 15 and a high estimate of 55. The average target predicts an increase of 378.96% from the current stock price of 6.89.
Analyst Consensus: Buy
* Price targets were last updated on May 9, 2024.
Analyst Ratings
The average analyst rating for VERV stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +117.71% | May 9, 2024 |
| Stifel | Stifel | Strong Buy Maintains $56 → $40 | Strong Buy | Maintains | $56 → $40 | +480.55% | Apr 3, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $35 | Buy | Reiterates | $35 | +407.98% | Feb 28, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $22 | Hold | Reiterates | $22 | +219.30% | Sep 13, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $22 | Hold | Reiterates | $22 | +219.30% | Aug 29, 2023 |
Financial Forecast
Revenue This Year
15.59M
from 11.76M
Increased by 32.56%
Revenue Next Year
9.27M
from 15.59M
Decreased by -40.51%
EPS This Year
-2.74
from -3.12
EPS Next Year
-2.98
from -2.74
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 46.9M | 25.8M | 47.3M | 21.7M | 96.6M |
| Avg | 15.6M | 9.3M | 15.0M | 7.8M | 26.4M |
| Low | 5.6M | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 299.2% | 65.7% | 409.6% | 45.4% | 1,146.1% |
| Avg | 32.6% | -40.5% | 61.2% | -48.1% | 240.0% |
| Low | -52.5% | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.50 | -2.36 | -2.23 | -1.69 | -1.74 |
| Avg | -2.74 | -2.98 | -2.93 | -2.99 | -3.00 |
| Low | -2.98 | -3.52 | -3.43 | -4.28 | -3.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.